CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inhibitor Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inhibitor Therapeutics Inc
4830 W. Kennedy Blvd., Suite 600
Phone: (813) 766-2462p:813 766-2462 TAMPA, FL  33609  United States Ticker: INTIINTI

This company was Merged or Acquired on 11/2/2016.
This is a Subsidiary, click here for the Parent Company

Business Summary
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders. It also explores acquiring or licensing other pre-clinical and clinical stage therapeutics addressing unmet needs and orphan indications for the treatment of cancer and other diseases. The Company’s primary focus is on the development of therapies initially for BCCNS, prostate and lung cancers in the United States utilizing Itraconazole, in a patent-protected formulation. It has conducted a Phase IIb study of SUBA-Itraconazole for the treatment of Basal Cell Carcinoma Nevus Syndrome, and Mayne Pharma assumed control of the clinical and regulatory development of this formulation for this indication.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYesYes-Yes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer Francis E.O'Donnell 73 12/13/2022 12/13/2022
Chief Financial Officer, Treasurer, Secretary James A.Mcnulty 72 12/13/2022 12/13/2022
Director Ronald E.Osman 77 8/23/2023 8/23/2023
4 additional Officers and Directors records available in full report.

Business Names
Business Name
HEDGEPATH PHARMACEUTICALS, INC.
HPPI
INTI
Mimotopes Pty Ltd
Tripos Discovery Research Limited
Tripos Discovery Research Products and Services

General Information
Number of Employees: 3 (As of 12/31/2022)
Outstanding Shares: 172,023,545 (As of 11/13/2023)
Shareholders: 64
Stock Exchange: OTC
Federal Tax Id: 300793665
Fax Number: (813) 527-0500
Email Address: INFO@CBI-BIOTECH.COM


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024